網膜静脈閉塞症の世界市場予測

【英語タイトル】Global Retinal Vein Occlusion Market Research Report - Forcast To 2023

Market Research Futureが出版した調査資料(MRF805008)・商品コード:MRF805008
・発行会社(調査会社):Market Research Future
・発行日:2018年2月5日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(印刷不可)USD4,450 ⇒換算¥502,850見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,250 ⇒換算¥706,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

IntroductionRetinal vein occlusion is a retinal vascular disease that mainly affects the older population and causes blindness. The condition is basically of two types, namely, Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO). BRVO is the condition when the blockage occurs in the branch of the retinal vein and blood with fluid spills out into the retina. On the other hand, CRVO is the condition when the blockage occurs in the main retinal vein and blood, and fluid spills out into the retina.
It is noted that the increasing prevalence of diabetes and atherosclerosis, is the key factor driving the retinal vein occlusion market. Various other factors such as the increasing prevalence of glaucoma, lymphoma, and multiple myeloma, and change in lifestyles are also propelling the growth of the market.
The global retinal vein occlusion market is segmented by type, condition, diagnosis, treatment, end-user, and region.
The market for retinal vein occlusion, by type, is segmented into branch retinal artery occlusion and central retinal vein occlusion, in which the branch retinal artery occlusion accounted for the largest market share in 2016. The branch retinal artery occlusion is expected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market is further segmented, by condition. The condition segment is classified as non-ischemic and ischemic. The non-ischemic segment is projected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market, by diagnosis, is segmented into Optical Coherence Tomography (OCT), fundoscopic examination, fluorescein angiography, and others. The fundoscopic examination segment is projected to grow at the fastest CAGR of 11.6% during the forecast period from 2017–2023.
The retinal vein occlusion market, by treatment, is segmented into antivascular endothelial growth factor, corticosteroid drugs, laser retinal photocoagulation, and others. The corticosteroid drugs segment is projected to grow at the fastest CAGR of 11.64% during the forecast period from 2017–2023.

Further, the market is segmented by end-user, which includes hospitals and clinics, research and academics center, and others. Hospitals and clinics accounted for the largest market share in 2016.
By region, the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The European region captured the largest market globally and is expected to reach USD 15,889.59 million by 2023.
Key Players
Some of the key players in this market are Allergan Plc, Bayer, Bristol-Myers Squibb, Ellex Medical Lasers Ltd., GlaxoSmithKline plc, IRIDEX Corporation, Lumenis, Novartis, NIDEK CO., LTD., Regeneron Pharmaceuticals, F. Hoffmann-La Roche AG, Quantel Medical Inc, Topcon Medical Systems, Inc., and ZEISS.

Study objectives
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide historical and forecast revenue of market segments based on type, condition, diagnosis, treatment, end-user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global retinal vein occlusion market
• To provide a detailed analysis of the value chain and supply chain of the global retinal vein occlusion market
Target Audience
• Pharmaceutical and Biotech Industries
• Potential Investors
• Medical Research Institutes
• Key Executive (CEO and COO) and Strategy Growth Manager
• Research Companies
Key Findings
• The global retinal vein occlusion market is expected to grow at a rate of 11.2% during the forecast period, 2017 to 2023. The increasing R&D spending, growing healthcare industry, and increased spending on technological advancements are driving the growth of the market
• The branch retinal artery occlusion segment commanded the largest market share in terms of type, in 2016, and is expected to register a CAGR of 11.6% during the forecast period, 2017–2023
• However, the high cost of treatment and side-effects associated with it may hinder the growth of the market

Regional Analysis
Americas
• North America
o U.S.
o Canada
• South America
Europe
• Western Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Western Europe
• Eastern Europe
Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia Pacific
Middle East & Africa
• Middle East
o United Arab Emirates
o Saudi Arabia
o Kuwait
o Qatar
o Africa

【レポートの目次】

Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing prevalence of diabetes and atherosclerosis (Impact Weightage 40%)
4.2.2 Change in lifestyle (Impact Weightage 35%)
4.2.3 Increasing prevalence of glaucoma, lymphoma, and multiple myeloma (Impact Weightage 25%)
4.3 Restraints
4.3.1 Side effect of treatment (Impact Weightage 60%)
4.3.2 High cost of treatment (Impact Weightage 40%)
5 Market Factor Analysis
5.1 Porters Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Retinal Vein Occlusion Market, By Type
6.1 Branch Retinal Artery Occlusion
6.2 Central Retinal Vein Occlusion
7 Global Retinal Vein Occlusion Market, By Condition
7.1 Non-Ischemic
7.2 Ischemic
8 Global Retinal Vein Occlusion Market, By Diagnosis
8.1 Optical Coherence Tomography
8.2 Fundoscopic Examination
8.3 Fluorescein Angiography
9 Global Retinal Vein Occlusion Market, By Treatment
9.1 Antivascular Endothelial Growth Factor
9.1.1 Aflibercept
9.1.2 Ranibizumab
9.2 Corticosteroid Drugs
9.2.1 Triamcinolone Acetonide
9.2.2 Dexamethasone
9.3 Laser Retinal Photocoagulation
10 Global Retinal Vein Occlusion Market, By End User
10.1 Hospitals and Clinics
10.2 Research & Academics Centers
11 Global Retinal Vein Occlusion Market, By Region
11.1 Americas
11.1.1 North America
11.1.1.1 U. S.
11.1.1.2 Canada
11.1.2 South America
11.2 Europe
11.2.1 Western Europe
11.2.1.1 Germany
11.2.1.2 France
11.2.1.3 U.K
11.2.1.4 Italy
11.2.1.5 Spain
11.2.1.6 Rest of Western Europe
11.2.2 Eastern Europe
11.3 Asia Pacific
11.3.1 Japan
11.3.2 China
11.3.3 India
11.3.4 Australia
11.3.5 Republic of Korea
11.3.6 Rest of Asia Pacific
11.4 Middle East & Africa
11.4.1 Africa
12 Competitive Landscape
12.1 Introduction
12.2 Company Share Analysis
13 Company Profiles
13.1 Allergan Plc
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Products
13.1.4 Strategy
13.1.5 Key Developments
13.2 Bayer
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Products
13.2.4 Strategy
13.2.5 Key Developments
13.3 Bristol-Myers Squibb
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Products
13.3.4 Strategy
13.3.5 Key Developments
13.4 Ellex Medical Lasers Ltd.
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Products
13.4.4 Strategy
13.4.5 Key Developments

13.5 GlaxoSmithKline plc
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Products
13.5.4 Strategy
13.5.5 Key Developments
13.6 IRIDEX Corporation
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Products
13.6.4 Strategy
13.6.5 Key Developments
13.7 Lumenis
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Products
13.7.4 Strategy
13.7.5 Key Developments
13.8 Novartis
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Products
13.8.4 Strategy
13.8.5 Key Developments
13.9 NIDEK CO.,LTD.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Products
13.9.4 Strategy
13.9.5 Key Developments
13.1 Regeneron Pharmaceuticals
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Products
13.10.4 Strategy
13.10.5 Key Developments
13.11 F. Hoffmann-La Roche AG
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Products
13.11.4 Strategy
13.11.5 Key Developments

13.12 Quantel Medical Inc
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Products
13.12.4 Strategy
13.12.5 Key Developments
13.13 Topcon Medical Systems, Inc.
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Products
13.13.4 Strategy
13.13.5 Key Developments
13.14 ZEISS
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Products
13.14.4 Strategy
13.14.5 Key Developments
14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs
14.2 Key companies to watch
15 Appendix
15.1 Discussion Blue Print

List of Tables:

TABLE 1 PRIMARY INTERVIEWS
TABLE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR BRANCH RETINAL ARTERY OCCLUSION, BY REGION, 2014-2023 (USD MILLION)
TABLE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2014-2023 (USD MILLION)
TABLE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR NON-ISCHEMIC, BY REGION, 2014-2023 (USD MILLION)
TABLE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ISCHEMIC, BY REGION, 2014-2023 (USD MILLION)
TABLE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2014-2023 (USD MILLION)
TABLE 7 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FUNDOSCOPIC EXAMINATION, BY REGION, 2014-2023 (USD MILLION)
TABLE 8 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR FLUORESCEIN ANGIOGRAPHY, BY REGION, 2014-2023 (USD MILLION)
TABLE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2014-2023 (USD MILLION)
TABLE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR AFLIBERCEPT, BY REGION, 2014-2023 (USD MILLION)
TABLE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RANIBIZUMAB, BY REGION, 2014-2023 (USD MILLION)
TABLE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR CORTICOSTEROID DRUGS, BY REGION, 2014-2023 (USD MILLION)
TABLE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR TRIAMCINOLONE ACETONIDE, BY REGION, 2014-2023 (USD MILLION)
TABLE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR DEXAMETHASONE, BY REGION, 2014-2023 (USD MILLION)
TABLE 15 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR LASER RETINAL PHOTOCOAGULATION, BY REGION, 2014-2023 (USD MILLION)
TABLE 16 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2014-2023 (USD MILLION)
TABLE 17 GLOBAL RETINAL VEIN OCCLUSION MARKET FOR RESEARCH & ACADEMICS CENTERS, BY REGION, 2014-2023 (USD MILLION)
TABLE 18 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY REGION, 2014-2023 (USD MILLION)
TABLE 19 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 20 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 21 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 22 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 23 AMERICAS ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 24 AMERICAS CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 25 AMERICAS RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 26 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION)
TABLE 27 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 28 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 29 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 30 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 31 NORTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 32 NORTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 33 NORTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 34 U.S. RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 35 U.S. RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 36 U.S. RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 37 U.S. RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 38 U.S. ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 39 U.S. CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 40 U.S. RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 41 CANADA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 42 CANADA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 43 CANADA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 44 CANADA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 45 CANADA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 46 CANADA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 47 CANADA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 48 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 49 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 50 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 51 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 52 SOUTH AMERICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 53 SOUTH AMERICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 54 SOUTH AMERICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 55 EUROPE RETINAL VEIN OCCLUSION MARKET, BY REGION, 2014-2023 (USD MILLION)
TABLE 56 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 57 EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 58 EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 59 EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 60 EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 61 EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 62 EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 63 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION)
TABLE 64 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 65 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 66 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 67 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 68 WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 69 WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 70 WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 71 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 72 GERMANY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 73 GERMANY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 74 GERMANY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 75 GERMANY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 76 GERMANY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 77 GERMANY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 78 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 79 FRANCE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 80 FRANCE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 81 FRANCE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 82 FRANCE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 83 FRANCE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 84 FRANCE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 85 U.K RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 86 U.K RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 87 U.K RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 88 U.K RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 89 U.K ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 90 U.K CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 91 U.K RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 92 ITALY RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 93 ITALY RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 94 ITALY RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 95 ITALY RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 96 ITALY ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 97 ITALY CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 98 ITALY RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 99 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 100 SPAIN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 101 SPAIN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 102 SPAIN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 103 SPAIN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 104 SPAIN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 105 SPAIN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 106 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 107 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 108 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 109 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 110 REST OF WESTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 111 REST OF WESTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 112 REST OF WESTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 113 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 114 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 115 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 116 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 117 EASTERN EUROPE ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 118 EASTERN EUROPE CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 119 EASTERN EUROPE RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 120 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY COUNTRY, 2014-2023 (USD MILLION)
TABLE 121 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 122 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 123 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 124 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 125 ASIA PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 126 ASIA PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 127 ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 128 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 129 JAPAN RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 130 JAPAN RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 131 JAPAN RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 132 JAPAN ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 133 JAPAN CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 134 JAPAN RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 135 CHINA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 136 CHINA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 137 CHINA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 138 CHINA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 139 CHINA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 140 CHINA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 141 CHINA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 142 INDIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 143 INDIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 144 INDIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 145 INDIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 146 INDIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 147 INDIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 148 INDIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 149 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 150 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 151 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 152 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 153 AUSTRALIA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 154 AUSTRALIA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 155 AUSTRALIA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 156 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 157 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 158 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 159 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 160 REPUBLIC OF KOREA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 161 REPUBLIC OF KOREA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 162 REPUBLIC OF KOREA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 163 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 164 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 165 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 166 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 167 REST OF ASIA PACIFIC ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 168 REST OF ASIA PACIFIC CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA MEDICAL IMPLANTS MARKET, BY REGION, 2014-2023 (USD MILLION)
TABLE 171 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 172 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 173 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, AW2014-2023 (USD MILLION)
TABLE 174 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 175 MIDDLE EAST & AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 177 MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 178 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 179 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 180 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 181 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 182 MIDDLE EAST ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 183 MIDDLE EAST CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 184 MIDDLE EAST RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)
TABLE 185 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 186 AFRICA RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2014-2023 (USD MILLION)
TABLE 187 AFRICA RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2014-2023 (USD MILLION)
TABLE 188 AFRICA RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2014-2023 (USD MILLION)
TABLE 189 AFRICA ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 190 AFRICA CORTICOSTEROID DRUGS MARKET, BY TYPE, 2014-2023 (USD MILLION)
TABLE 191 RETINAL VEIN OCCLUSION MARKET, BY END USER, 2014-2023 (USD MILLION)



List of Figures:

FIGURE 1 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2016 (%)
FIGURE 2 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2016 (%)
FIGURE 3 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2016 (%)
FIGURE 4 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2016 (%)
FIGURE 5 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2016 (%)
FIGURE 6 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY REGION, 2016 (%)
FIGURE 7 MARKET STRUCTURE OF GLOBAL RETINAL VEIN OCCLUSION MARKET
FIGURE 8 RESEARCH METHODOLOGY
FIGURE 9 GLOBAL RETINAL VEIN OCCLUSION MARKET: FORECAST MODEL
FIGURE 10 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TYPE, 2016 & 2023 (%)
FIGURE 11 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY CONDITION, 2016 & 2023 (%)
FIGURE 12 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY DIAGNOSIS, 2016 & 2023 (%)
FIGURE 13 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY TREATMENT, 2016 & 2023 (%)
FIGURE 14 GLOBAL RETINAL VEIN OCCLUSION MARKET, BY END USER, 2016 & 2023 (%)



【レポートのキーワード】

網膜静脈閉塞症

★調査レポート[網膜静脈閉塞症の世界市場予測] (コード:MRF805008)販売に関する免責事項を必ずご確認ください。
★調査レポート[網膜静脈閉塞症の世界市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆